Potent glycogen synthase kinase-3 (GSK-3) inhibitor (Ki
= 0.6 nM for GSK-3α
). Displays high selectivity (> 50-fold) for GSK-3 over a panel of other kinases tested, including CDK family members. Decreases phosphorylation of microtubule-associated protein Tau in vitro
; protects rat primary cortical neurons against β
amyloid and glutamate challenge. Brain penetrant.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
A-1070722, a potent, selective, and centrally active glycogen synthase kinase-3 (GSK-3) inhibitor for the treatment of psychiatric and neurodegenerative disorders.
Bakker et al.
Society for Neuroscience (Abstract), 2011;:568